Medicines n Vaccines Treat COVID-19 FDA Approved Research Progress
Research and development made against the spreading of the Coronavirus haven’t all gone in vain. Researchers came up with medicines which they believe to be effective if not completely and would definitely cause a positive effect. The medicines have been used and effects have been observed. Medical community from the United States stated the use of some of the medicines which they believe are “some how” useful against the Coronavirus. These medicines may not be perfect but they can be used as a side treatment. There are no particular ways to kill a virus. However, naturally it completes its reproductive cycle and leaves the body causing a lot of harm. More of the fluid secretion from the body is known to be the best solution till now. But the medicines being used till now and what sort of benefit we have from them will be discussed today. Our sources around the world have progressively informed us about some of the medicines and the development of vaccines by several departments and what they have to say for it. Lets have a look
The Hydroxychloroquine was being used against malaria before the outbreak of the Coronavirus. This anti malarial drug was known as quite effective against malaria and the agent plasmodium that causes it, rheumatoid arthritis and lupus erythematous. Hydroxychloroquine regulates and prevents the breakdown of the hemoglobin in red blood cells. Currently hydroxychloroquine is being used in the same way to prevent or resist the flow of the Coronavirus. The FDA issued an emergency use authorization for hydroxychloroquine and chloroquine for use in COVID-19 on March 28, 2020.
It is being studied for SARS-coV-2 and Henipavirus infections. Based on success against other coronavirus infections, Gilead provided remdesivir to physicians who treated an American patient in Snohomish County, Washington in 2020, who was infected with SARS-CoV-2. Remdesivir is an antiviral drug that was being used as an effect treatment against ebola. Ebola happens to be transferred from bats and is one heck of a virus. However, remdesivir was found very successful against it. Researchers are quite familiar with the reaction of remdesivir against ebola and its scientific methods but they are not sure how it could tackle the Coronavirus if it does not recognize it. The virus is tricked into incorporating the active form of the drug into its genome, preventing it from making more copies of itself. Making it as the currently most useful antiviral drug.
Avigan or favipiravir is anti flu agent that has been working perfectly against flu. Coronavirus also causes respiratory infection or pneumonia leading to shortness of breath, dry cough and fever. Chinese officials believe that favipiravir has also turned out quite effective against the Coronavirus. The favipiravir group also showed significant improvement in chest imaging compared with the control arm, with an improvement rate of 91.43% versus 62.22%. Avigan may not kill the virus but it definitely causes betterment to the issues it causes.
Russian scientists have put forward a claim that lopinavir has turned out amazing against mild coronavirus. In a recommendation published on the Moscow City Health Department’s website Wednesday, the experts prescribed the medicine to patients being treated at home. Our sources confirmed that it is prescribed to patients with a coronavirus infection who are being treated at home: Lopinavir+Ritonavir 400mg/100mg every 12 hours for 14 days. Pathogenesis treatment (a therapy, aiming to fight the origin and development of the disease) Rehydrating drink. Plentiful drink, the recommendation said. Presently Lopinavir is being used against HIV and AIDS.
Tocilizumab is also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor. Recently approved by FDA to be randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the safety and efficacy of intravenous (IV) tocilizumab (Actemra) plus standard of care in hospitalized adult patients with severe coronavirus disease 2019 (COVID-19) pneumonia, according to Genentech, the agent’s developer.
List of Vaccines Which are Under Clinical Testing
Other than the currently known medicines listed above, researchers are developing vaccines which sources believe would be the direct extinction of the virus.
1. Fusogenix DNA vaccine by Entos Pharmaceuticals
Entos Pharmaceuticals are currently in the process of developing fusogenix vaccines made through fusogenix drug delivery platform to avoid CONVID-19 infection.
Our sources at Entos Pharmaceuticals were informed about how the Fusogenix drug delivery platform is a proteo-lipid vehicle that introduces genetic payload directly into the cells and that Entos is currently functioning on developing an optimised payload containing multiple protein epitopes derived from SARS-COV-2 (Coronavirus) proteins, by doing so we can stimulate an immune response in the body to prevent COVID-19 infection. Ultimately it can be a key killer of the virus.
2. ChAdOx1 nCoV-19 by University of Oxford
ChAdOx1 nCoV-19 is an adenovirus vaccine vector developed by the university’s Jenner Institute. Presently not much is known about the vaccine. However, 510 subjects of age 18-55 will be sooner enrolled for further testing.
3. Gimsilumab by Roivant Sciences
Gimsilumab is another drug under research by Roviant sciences. Our sources have been informed that the drug targets granulocyte-macrophage colony stimulating factor (GM-CSF), which is a pro-inflammatory cytokine found in high levels in the serum of COVID-19 patients. This would work effectively against lung damage.
4. AdCOVID by Altimmune
Altimmune is on a special task, developing an intranasal vaccine for the CONVID-19 named as AdCOVID. It is stated that Altimmune and UAB will work with researchers to conduct preclinical animal studies and phase one clinical trial in the third quarter of 2020.
5. TZLS-501 by Tiziana Life Sciences
Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. Much advancement has been made till now. It is claimed that TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6. The drug works by binding to IL-6R and depleting the amount of IL-6 circulating in the body thereby reducing chronic lung inflammation.